Get all your news in one place.
100's of premium titles.
One app.
Start reading
Barchart
Barchart
Kritika Sarmah

Are Wall Street Analysts Predicting Regeneron Pharmaceuticals Stock Will Climb or Sink?

Tarrytown, New York-based Regeneron Pharmaceuticals, Inc. (REGN) is a leading biotechnology company focused on discovering, developing, and commercializing medicines for serious diseases. The company has a market capitalization of $83.7 billion and has become one of the largest biotech firms in the world through its expertise in antibody technologies, genetics-driven drug discovery, and innovative biologic therapies.

The biotech titan's shares have underperformed the broader market over the past year and in 2026. REGN stock has surged 7% over the past 52 weeks and is down 17.2% on a YTD basis. In comparison, the S&P 500 Index ($SPX) has returned 27.9% over the past year and 9.2% in 2026.

Sign up to read this article
Read news from 100's of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.